Nanosphere technology will be utilized for controlled ophthalmic antibiotic delivery via a hydrogel polymer contact lens device. The device will be useful for a number of conditions including traumatic injury, surface disorders, and post-surgical healing. The advantage of this medicated bandage system over traditional therapy is that a consistent dose of antibiotic (ciprofloxacin) will be delivered over a 7-14 day period while protecting the cornea with a hydrogel bandage lens. The sustained delivery of ciprofloxacin precludes the use of topical antibiotic drops, resulting in improved patient compliance, convenience, and subsequent efficacy. The bandage effect of the device assists in pain relief and wound healing at the surface of the eye, as is commonly done using current, non-medicated hydrogel bandage contact lenses. The nanosphere technology utilized in this project allows for customized encapsulation to control drug release. These nanospheres are unique in that they are based on a carbohydrate core, and have a hydrophilic shell rendering it compatible with a hydrophilic system such as our hydrogel contact lens material. They are biodegradable, non-toxic, and stable in solution. Both the shell and the core can be functionalized independently, allowing for modifications and enhancements to further control drug release.
The specific aims of this project during year 1 include synthesis of the nanospheres and encapsulation of the antibiotic;polymerization of the nanospheres into the hydrogel material suitable for ocular use;and testing the release characteristics of the antibiotic from the hydrogel lenses. During year 2 of this project, the casting and manufacturing specifics for the lenses will be determined, and the pre-clinical safety and efficacy of the lenses will be tested, according to FDA guidelines.

Public Health Relevance

The product in development will improve patient care by providing a more efficient, convenient, and consistent means of antibiotic drug delivery to the surface of the eye, while serving as a bandage to decrease intense ocular pain and to aid in ocular surface healing. This product will eliminate the necessity of giving frequent doses of antibiotic drops for a wide range of conditions compromising the surface of the eye. Such common conditions include active infections of the cornea and conjunctiva, as well as for prevention of pain or potential infection associated with severe dry eye, trauma, or ocular surgery such as cataract, glaucoma or laser refractive surgery procedures.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
5R43EY018960-02
Application #
7666115
Study Section
Special Emphasis Panel (ZRG1-BDCN-F (12))
Program Officer
Wujek, Jerome R
Project Start
2008-08-01
Project End
2011-01-31
Budget Start
2009-08-01
Budget End
2011-01-31
Support Year
2
Fiscal Year
2009
Total Cost
$186,614
Indirect Cost
Name
Vista Scientific, LLC
Department
Type
DUNS #
119893121
City
Andover
State
MA
Country
United States
Zip Code
01810
Shady, Sally Fouad; Gaines, Peter; Garhwal, Rahul et al. (2013) Synthesis and characterization of pullulan-polycaprolactone core-shell nanospheres encapsulated with ciprofloxacin. J Biomed Nanotechnol 9:1644-55
Garhwal, Rahul; Shady, Sally F; Ellis, Edward J et al. (2012) Sustained ocular delivery of ciprofloxacin using nanospheres and conventional contact lens materials. Invest Ophthalmol Vis Sci 53:1341-52